KR910004617A - 치환된 피라진, 이의 제형 및 약제로서의 용도 - Google Patents

치환된 피라진, 이의 제형 및 약제로서의 용도 Download PDF

Info

Publication number
KR910004617A
KR910004617A KR1019900012128A KR900012128A KR910004617A KR 910004617 A KR910004617 A KR 910004617A KR 1019900012128 A KR1019900012128 A KR 1019900012128A KR 900012128 A KR900012128 A KR 900012128A KR 910004617 A KR910004617 A KR 910004617A
Authority
KR
South Korea
Prior art keywords
salt
compound
chloropyrazin
azabicyclo
octane
Prior art date
Application number
KR1019900012128A
Other languages
English (en)
Inventor
베이커 레이몬드
사운더스 존
제이.스트리트 레슬리
Original Assignee
알란 헤스케쓰
머크 샵 앤드 돔 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알란 헤스케쓰, 머크 샵 앤드 돔 리미티드 filed Critical 알란 헤스케쓰
Publication of KR910004617A publication Critical patent/KR910004617A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음.

Description

치환된 피라진, 이의 제형 및 약제로서의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 화합물 (R)-3-[2-(6-클로로피라진)일]-1-아자비사이클로[2.2.2]옥탄 또는 이의 염.
  2. 제1항에 있어서, 하이드로클로라이드, 수소 말레에이트, 세스퀴옥살레이트 또는 수소 타르트레이트 염인 화합물.
  3. (a) 하기 일반식(VIII)의 화합물 또는 이의 염을 환화시키거나; (b) 3-[2-(6-클로로피라진)일]-1-아자비사이클로[2.2.2]옥탄의 에난티오머를 분할하고; 임의로는 상기와 같이 제조된 화합물과 산을 반응시킴으로써 이의 산 부가염을 제조함을 특징으로 하여, 제1항 또는 제2항에 따른 화합물 또는 이의 염을 제조하는 방법.
    상기식에서, R4는 불안정한 이탈 그룹이다.
  4. 제3(a)항에 있어서, R4가 메실레이트 또는 할로인 방법.
  5. 제3(a)항 또는 4항에 있어서, 일반식(VIII)의 염이 하이드로클로라이드인 방법.
  6. 제3(a)항에 있어서, 키랄산을 사용하여 분할하는 방법.
  7. (R)-3-[2-(6-클로로피라진)일]-1-아자비사이클로[2.2.2]옥탄 또는 약제학적으로 허용되는 이의 염 및 약제학적으로 허용되는 담체를 포함함을 특징으로 하는 제약학적 조성물.
  8. (R)-3-[2-(6-클로로피라진)일]-1-아자비사이클로[2.2.2]옥탄 또는 약제학적으로 허용되는 이의 염 및 약제학적으로 허용되는 담체 혼합시킴을 특징으로 하여, 제7항에 따른 조성물을 제조하는 방법.
  9. 환자에게 (R)-3-[2-(6-클로로피라진)일]-1-아자비사이클로[2.2.2]옥탄 또는 약제학적으로 허용되는 이의 염을 투여함을 특징으로 하여, 신경 질환 및 정신 질환을 치료 또는 예방하는 방법.
  10. 제9항에 있어서, 질환이 치매인 방법.
  11. 제3항 내지 제6항중 어느 한 항에 따른 방법에 의해 제조된 제1항 또는 제2항의 화합물.
  12. 제8항에 따른 방법에 의해 제조된 제7항의 제형.
  13. 실질적으로 본 발명의 상세한 설명 및 실시예와 관련하여 기술된 화합물, 제형 및 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900012128A 1989-08-08 1990-08-08 치환된 피라진, 이의 제형 및 약제로서의 용도 KR910004617A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8918060.8 1989-08-08
GB898918060A GB8918060D0 (en) 1989-08-08 1989-08-08 Therapeutic agents

Publications (1)

Publication Number Publication Date
KR910004617A true KR910004617A (ko) 1991-03-29

Family

ID=10661305

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900012128A KR910004617A (ko) 1989-08-08 1990-08-08 치환된 피라진, 이의 제형 및 약제로서의 용도

Country Status (13)

Country Link
US (1) US5073557A (ko)
EP (1) EP0416754A3 (ko)
JP (1) JPH03135979A (ko)
KR (1) KR910004617A (ko)
AU (1) AU6083090A (ko)
CA (1) CA2022885A1 (ko)
FI (1) FI903919A0 (ko)
GB (1) GB8918060D0 (ko)
IE (1) IE902875A1 (ko)
IL (1) IL95312A0 (ko)
NO (1) NO903484L (ko)
PT (1) PT94921A (ko)
ZA (1) ZA906251B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK72790D0 (da) * 1990-03-21 1990-03-21 Ferrosan As Heterocycliske forbindelser, deres fremstilling og anvendelse
GB9017353D0 (en) * 1990-08-08 1990-09-19 Merck Sharp & Dohme Chemical process
CA2050264A1 (en) * 1990-08-30 1992-03-01 Raymond Baker Substituted pyrazine and its salts, compositions containing them and their use in medicine
GB9201749D0 (en) * 1992-01-28 1992-03-11 Smithkline Beecham Plc Medicaments
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442096A (en) * 1982-12-27 1984-04-10 Merck & Co., Inc. 2-(Substituted)amino-3-cyano-5-halo-6-(substituted)-pyrazine antimicrobial compounds, compositions and use
DE3515709C1 (de) * 1985-05-02 1986-12-18 Union Rheinische Braunkohlen Kraftstoff AG, 5000 Köln Verfahren zum Reinigen von fluessigem Schwefel
NZ219646A (en) * 1986-03-27 1990-10-26 Merck Sharp & Dohme Oxadiazole derivatives of azacyclics for treating cns disorders
NZ227684A (en) * 1988-01-30 1991-07-26 Merck Sharp & Dohme Pyrazine, pyridazine, and pyrimidine derivatives and pharmaceutical compositions
DE58906678D1 (de) * 1988-07-28 1994-02-24 Ciba Geigy Kupfer- und Nickeldihalogenidkomplexe, Verfahren zu deren Herstellung und deren Verwendung.

Also Published As

Publication number Publication date
EP0416754A3 (en) 1991-11-27
GB8918060D0 (en) 1989-09-20
FI903919A0 (fi) 1990-08-08
US5073557A (en) 1991-12-17
NO903484L (no) 1991-02-11
CA2022885A1 (en) 1991-02-09
ZA906251B (en) 1991-07-31
EP0416754A2 (en) 1991-03-13
IL95312A0 (en) 1991-06-30
IE902875A1 (en) 1991-02-27
JPH03135979A (ja) 1991-06-10
NO903484D0 (no) 1990-08-08
PT94921A (pt) 1991-04-18
AU6083090A (en) 1991-02-14

Similar Documents

Publication Publication Date Title
KR100432825B1 (ko) 식이 장애 치료용 약제학적 조성물
KR900018087A (ko) 옥사디아졸 및 이의염, 치매를 치료하기 위한 이의 용도, 이의 제조방법 및 제제
US4859709A (en) Pharmaceutical composition
DE60111265T2 (de) Pharmazeutische zusammensetzungen mit nmda-rezeptor-agonist
US6025502A (en) Enantopselective synthesis of methyl phenidate
EP0279990B1 (en) Use of heterocyclic derivatives in the treatment of cognitive disorders
KR920012061A (ko) α-옥소아세트아미드 유도체
DE69819891T2 (de) Spiro chinuclidin-derivate, ihre herstellung und verwendung
CZ286325B6 (cs) Amidy kyseliny indazolylkarboxylové, farmaceutické prostředky s obsahem těchto látek
EP0188081A2 (en) Use of paroxetine for the manufacture of a medicament for the treatment of obesity
KR920009828A (ko) 신규의 삼환식 화합물
EP0193148A3 (en) 8-Chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-(alkoxy-containing acyl)hydrazides
KR930019669A (ko) 신놀린-3-카르복실산 유도체
EP0276559A2 (en) Use of ketone derivatives in the treatment of depression
KR910009707A (ko) 피소스타그민에 관련된 아미노카보닐카바메이트, 이의 제조방법 및 이의 약제로서의 용도
KR950014103A (ko) 1-[2H-1-벤조피란-2-온-8-일]-피페라진 유도체(1-[2H-1-benzopyran-2-one-8-yl]-piperazine derivatives)
KR840001553B1 (ko) 시클로헥센 유도체의 제조방법
KR910004617A (ko) 치환된 피라진, 이의 제형 및 약제로서의 용도
HU900255D0 (en) Process for preparation of 3-phenyl-5,6-dilhydrobenz (c)-acridine-carboxylic-acids and carboxylic-acid derivatives and for manufacturing of pharmaceutical composition containing these compounds as active ingredient
JP2877231B2 (ja) スピロキヌクリジン誘導体の光学異性体、それらの製造法、それらからなる薬剤組成物およびそれらを使用した治療法
DE1805029A1 (de) Oxotremorin-Antagonisten und Verfahren zu deren Herstellung
AP2001002367A0 (en) Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2]oct-3-yl)-5-isopropyl-2-methoxybenzyl)-ammoniumchloride as nk-1-receptor antagonists.
CA2378628A1 (fr) Nouveaux derives d'indenoindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JPS6413024A (en) Pharmaceutical composition
US4259346A (en) Bradycardiac pharmaceutical compositions and method of use

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid